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Specialty Update
What’s New in Musculoskeletal
Infection: Update on Bioﬁlms
Arvind Nana, MD, MBA, Sandra B. Nelson, MD, Alex McLaren, MD, and Antonia F. Chen, MD, MBA*
Investigation performed at the University of North Texas Health Science Center, Fort Worth, Texas; Massachusetts General Hospital, Harvard Medical
School, Boston, Massachusetts; Orthopaedic Surgery Residency, University of Arizona College of Medicine, Phoenix, Arizona; and Rothman Institute at
Thomas Jefferson University, Sidney Kimmel Medical College, Philadelphia, Pennsylvania
Infections involving orthopaedic surgical implants present
unique challenges when compared with infections that do not
involve implants. Microorganisms have a high afﬁnity for ad-
hering to foreign materials commonly used in orthopaedics,
including cobalt-chromium, titanium, polyethylene, and poly-
methylmethacrylate (PMMA) cement. When bacteria adhere
to these surfaces, they can form a complex structure sur-
rounded by a self-generated extracellular polymeric substance
(EPS) matrix formed by multiplex agents of biopolymers
consisting of proteins, polysaccharides, lipids, nucleic acids,
and humic substances1-3. The term “bioﬁlm” is commonly used
to describe this network of microorganisms, a term popular-
ized by Dr. J. William Costerton et al. in 19784.
Bioﬁlms are formed by a conﬂuence of bacteria com-
monly encountered in orthopaedic infections. Up to 65% of
bacterial infections are caused by bioﬁlm-producing organ-
isms5. Staphylococci, speciﬁcally Staphylococcus aureus
(S. aureus) and Staphylococcus epidermidis (S. epidermidis), are
the most common bioﬁlm-forming bacteria found in ortho-
paedics, and, when combined with Pseudomonas aeruginosa
(P. aeruginosa), they represent nearly 75% of bioﬁlm infec-
tions observed in medical devices6. Propionibacterium acnes
(P. acnes), an organism commonly found in shoulder infec-
tions, has also been shown to form bioﬁlm. Bioﬁlms can be
composed of a single organism or can be polymicrobial;
polymicrobial bioﬁlms are more difﬁcult to eradicate7.
Once bacteria adhere to the surface of implants, they may
replicate and may form a complex network of microorganisms
that communicate with one another via cell-to-cell signaling
that facilitates the participation of bacteria in quorum sensing7.
Quorum sensing serves as an elementary endocrine system
whereby bacteria sense the local cell population density and
regulate gene expression by releasing extracellular molecules to
facilitate synchronized changes in the bacteria within the bio-
ﬁlm. These transcriptional changes can occur with the ex-
change of plasmids between bacteria, which can confer genes
for virulence factors and antibiotic resistance, and can com-
mence the formation and secretion of the EPS matrix that
supports the bioﬁlm8. This matrix not only anchors bacteria to
orthopaedic implants, but it also provides a nearly impene-
trable defense mechanism as a result of the matrix serving as a
protective physical barrier for bacteria against the host immune
system9. This barrier also limits the ﬂow of ﬂuid within the
bioﬁlm, which reduces the amount of available nutrients; this
leads bacteria to enter a no-growth or diminished-growth state
that resists growth-dependent antimicrobial agents and renders
it difﬁcult for antibiotics to penetrate and eradicate bioﬁlms10.
There have been numerous new technologies developed
to detect bioﬁlms, to prevent bioﬁlm formation, or to disrupt
bioﬁlms to make them more susceptible to treatments. De-
tecting planktonic, or free-ﬂoating, bacteria can be achieved by
traditional culturing; however, bioﬁlm bacteria may be easier to
detect using molecular methods, such as polymerase chain
reaction (PCR), ﬂuorescence in situ hybridization (FISH), and
DNA microarrays11. Some antibiotics, including rifampicin,
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which inhibits transcription, and meropenem, which inhibits
cell wall biosynthesis, demonstrate antibioﬁlm activity12,13.
Other medications with different mechanisms, such as those
that inhibit quorum sensing and bacteriophage therapy to
disrupt the bioﬁlm’s extracellular matrix, have shown some
promise against bioﬁlms and remain an active area of investi-
gation14,15. Physical methods to disrupt bioﬁlms using ultra-
sound and electrotherapy may be used in conjunction with
other chemical methods of treating bioﬁlms16.
There are numerous avenues by which the prevention
and treatment of bioﬁlm infections continue to be explored in
orthopaedics. The purposes of this orthopaedic infection up-
date are to describe the basic science of bioﬁlm formation, to
detail published guidelines for the diagnosis and treatment of
bioﬁlm infections, and to explain modiﬁable factors in bioﬁlm
formation after orthopaedic trauma and total joint arthro-
plasty. We reviewed literature published in the past 24 months
to identify the studies most relevant to orthopaedics in both
basic science and clinical practice with regard to musculo-
skeletal infection, and they are presented below.
Bioﬁlm Basic Science
In 2015, bioﬁlm research was robust, with more investigations
published than any one clinician could keep up with. There
were 4,817 publications cited in PubMed during 2015, plus
another 907 in the ﬁrst 2 months of 2016. For publications on
the biology of bioﬁlms, there were 870 citations from January
2015 to February 2016 that crossed multiple disciplines, in-
cluding medicine (implant, bone, lung, urological), dentistry
(periodontal disease), industry (waste water sludge), agricul-
ture (plant, animal), and marine (ﬁsh, coral). Most of the basic
science reports were not in the orthopaedic literature. PubMed
identiﬁed only 82 citations as orthopaedic in 2015, plus 20
citations in January and February 2016. Myriad investigations
studying all aspects of bioﬁlm biology were reported; however,
3 important areas were noted: (1) quorum quenching (anti-
quorum sensing), (2) persister cells, and (3) use of anti-cancer
chemotherapy drugs to eradicate bioﬁlms.
Quorum sensing was identiﬁed in 246 citations in 2015,
with another 56 citations in January to February 2016; these
citations were dominated by ways to interrupt or to alter
quorum sensing as a strategy to prevent or disperse bioﬁlms,
using six microorganisms (Table I). Although acyl homoserine
lactone (AHL) from Pseudomonas was the dominant quorum-
sensing molecule (autoinducer) studied, quorum-quenching
strategies were all different. The theme was novel ideas in-
volving unstudied compounds that all had therapeutic poten-
tial. None of the strategies presented were near clinical use,
and none had corroboration. There were 19 molecular com-
pounds17-34, 19 plant-based compounds, 2 microorganism-
generated compounds (Table II), and 2 nanoscale surface
treatments (titania nanotubes35 and zinc oxide nanoparticles36).
Another strategy that was investigated was quorum quenching
to interrupt virulence factors rather than to prevent microor-
ganism growth and bioﬁlms37. Attention to small-molecule
anti-quorum-sensing agents carries the hope that resistance
will not occur; however, resistance to some agents has already
occurred38.
Persister cells with inherent tolerance to antimicrobials
were ﬁrst described in the 1940s in planktonic bacterial pop-
ulations. There were only 40 PubMed citations for persisters
and antimicrobial tolerance from 2006 to 2014. During 2015,
there were 15 citations covering the characteristics of persisters,
how they are formed, and potential eradication strategies39.
One major point is that surface adhesion is important for
persister cells to be present in bioﬁlm40. Two misconceptions
that permeate the literature need consideration. The ﬁrst
TABLE I Microorganisms Used in Quorum-Sensing Studies
Microorganism No. of Reports and References
Pseudomonas 2020,23-25,28-30,32,36,97-107
Staphylococcus 819,20,24,27,35,37,108,109
Acinetobacter baumannii 326,31,110
E. coli 328,111,112
Vibrio 4113-116
Candida 318,21,22
TABLE II Quorum-Quenching Compounds
Plant origin
Centella asiatica (spadeleaf)106
Piper delineatum ﬂavonoids114
Leucetta chagosensis113
Tannic acid103
Cannabinoid HU-210 (medical marijuana)116
Chamomile102
Nymphaea tetragona (water lily)100
Green tea polyphenols107
Pomegranate112
Cranberry105
Rosmarinic acid (rosemary)117
Petiveria alliacea101
Berberis aristata, Camellia sinensis, and Holarrhena
antidysenterica111
Quercetin (fruit and vegetable ﬂavonol)104
Clove bud oil99
Phytochemicals of various medicinal plants118
Coriandrum sativum (coriander)119
Microorganism origin
Glycyrrhiza glabra110
Halophilic marine Streptomyces120
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misconception is that persister cells cannot be killed. This is
not true, as they are reliably killed when the antimicrobial
concentration is high enough41. Minimum bioﬁlm eradication
concentration (MBEC) is widely used to refer to the concen-
tration needed to kill all persister cells41,42. Interestingly, the
MBEC is lower when antimicrobial exposure is continuous and
prolonged41. The second misconception is that a decreased
number of microorganisms after a speciﬁc intervention, either
in bioﬁlm or attached to a surface, is a measure of success.
Although this is considered good, it is not good enough. For
cure or prevention, total elimination of all viable microbes is
required. When any viable microbes remain, infection can
propagate.
Isolated in vitro investigations using chemotherapeutic
agents approved by the U.S. Food and Drug Administration
(FDA) for speciﬁc anti-cancer indications (cisplatin43, 5-
ﬂuorocytosine44, and mitomycin C45) showed eradication of
all bioﬁlm-embedded microbes, including persister cells, by
mechanisms that are not growth-dependent. This raises the
possibility that anti-cancer drugs may have a role in eradicating
bioﬁlms.
The extensive growth in research on bioﬁlms is an in-
dication of the need for clinically applicable knowledge. None
of the interventions detailed in this basic science review are
ready for general clinical application. Although understanding
of the fundamental biology of bioﬁlm-based infection is ex-
pected to increase the understanding and implementation of
current treatment protocols, clinical adoption of basic science
knowledge requires carefully designed and conducted clinical
trials. Recent reports on clinical treatment protocols are dis-
cussed below.
Guidelines for the Diagnosis and Treatment of
Bioﬁlm Infections
Bioﬁlms are found in many types of chronic infections, in-
cluding those involving native tissue (e.g., chronic sinusitis,
endocarditis, osteomyelitis) and those that infect indwelling
devices (e.g., catheter-associated bloodstream and urinary tract
infections, prosthetic valve endocarditis, vascular graft infec-
tions, ventriculoperitoneal shunt infections, and ventilator-
associated pneumonias). The challenges faced by orthopaedists
in treating bioﬁlm infections are also confronted by clinicians
in other disciplines. For example, the diagnosis of bioﬁlm in-
fections wherever they occur is challenged by non-planktonic
organisms that do not replicate readily in laboratory culture.
Decisions about device removal are also faced by surgeons and
other interventionalists treating bioﬁlm infections; these indi-
viduals must take into consideration the feasibility and mor-
bidity associated with device removal, the likelihood of a cure
in the setting of device retention, and the availability of anti-
microbials for long-term suppression if a cure is not achieved.
Clinicians treating bioﬁlm infections are often left with
controversies about the optimal approach to diagnosis and
management of bioﬁlm infections. Guidelines and/or consen-
sus statements have been developed for some bioﬁlm infections
in which data are more robust, such as endocarditis46; peri-
prosthetic joint infection, as stated by the Infectious Diseases
Society of America (IDSA)47, American Academy of Ortho-
paedic Surgeons (AAOS)48, and International Consensus
Meeting on Periprosthetic Joint Infection49; catheter-based
infections50; cardiac device infections51; otitis media52; and
ventilator-associated pneumonia53. However, for some bioﬁlm
infections, there are insufﬁcient data to generate meaningful
guidelines. Until recently, to our knowledge, there had been no
attempt to summarize recommendations on bioﬁlm infections.
In 2014, the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) developed guidelines for the
diagnosis and treatment of bioﬁlm infections54. The multidis-
ciplinary panel of 15 physician-scientists completed a system-
atic review of questions related to the prevention, diagnosis,
and treatment of bioﬁlm infections. The subject included bio-
ﬁlm infections for which other guidelines do not exist and
comprised both native tissue infections (chronic lung infec-
tions in cystic ﬁbrosis, chronic wound infections) and device-
associated infections (orthopaedic devices, endotracheal tubes,
intravenous catheters, urinary catheters and urethral stents,
tissue ﬁllers). Not surprisingly, although recommendations
could be made for some of the questions addressed, many had
insufﬁcient data from which to generate conclusions.
In collating data on multiple different types of bioﬁlm
infections, common themes nonetheless emerged. Preventive
strategies show promise, particularly the administration of
topical therapies in the setting of implanted devices. Topical
therapies recommended by the panel include the use of anti-
microbial PMMA bone cement to prevent infections associated
with orthopaedic devices, silver-coated endotracheal tubes to
prevent ventilator-associated pneumonia, and chlorhexidine-
impregnated sponges around central venous catheters to
prevent bloodstream infection. Systemic antimicrobial pro-
phylaxis is not widely effective; its use is only recommended for
surgical antibiotic prophylaxis against infections associated
with orthopaedic devices. Systemic prophylaxis against other
types of bioﬁlm infections has not been demonstrated to be
effective.
Diagnostic challenges persist across all types of bioﬁlm
infections. Persistent local inﬂammation may be the only
clinical clue to infection; however, this is not always speciﬁc for
infection. Further, bioﬁlms may colonize devices and may be
detected with microbiological means but may not be associated
with clinically important infection. Discerning whether infec-
tion is the cause of local inﬂammation is not always straight-
forward. For infections associated with orthopaedic devices,
the guidelines recommended tissue samples rather than swabs,
as bioﬁlm organisms may be strongly adherent to tissue. More
than one tissue culture is recommended and larger tissue
samples (up to 1 cm3) are favored. When orthopaedic and
other devices are explanted, sonication is suggested where
available to liberate sessile organisms within the bioﬁlm.
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Antimicrobial susceptibility focusing on planktonic organisms
should be determined, but it may not represent the heightened
resistance of sessile bioﬁlm organisms and may lead to treat-
ment failures. Bioﬁlm-speciﬁc antimicrobial susceptibility
methods have been designed but have not been clinically val-
idated and are not yet recommended.
Few conclusions could be drawn about optimal treat-
ment strategies, including for infections associated with or-
thopaedic devices. The ESCMID (European Society of Clinical
Microbiology and Infectious Diseases) Guidelines panel con-
cluded that eradication of some bioﬁlm infections is possible
without device explantation, although a cure cannot always be
predicted in advance54. More favorable outcomes are seen when
the duration of infection symptoms is short (when the bioﬁlm
is young) and when the infecting organisms are susceptible
to bioﬁlm-validated antimicrobials, such as rifampicins for
staphylococci and ﬂuoroquinolones for gram-negative infec-
tions. Combinations of local and systemic therapies can be
recommended for some bioﬁlm infections, including ortho-
paedic infections. Unfortunately, no tests are available that
inform when a bioﬁlm infection is clinically cured, as the
available surrogate tests can be inaccurate in the face of anti-
biotic therapy.
Although many questions remain unanswered, it is
hoped that the experience gained by this guideline review may
facilitate research into solutions that apply to multiple types
of bioﬁlm infections and thereby can transcend disciplines.
Bioﬁlm in Orthopaedic Trauma
In the ﬁeld of orthopaedic trauma, open fractures are injuries
in which there is concern of bioﬁlm formation from initial
presentation55 and are aptly described as “the race for the
surface” by Gristina et al.56. Implants also represent a surface on
which bioﬁlm may easily develop. With open fractures, bioﬁlm
can develop on bone and in soft tissues within a matter of
hours, especially when either is devitalized, and it competes
with the ability of bone to heal after a fracture.
Open fractures represent a broad spectrum of injury
because of the multitude of local and systemic host factors that
can potentially inﬂuence outcomes. Local host factors include,
but are not limited to: the extent of contamination; the size
of the open wound, including undermining; soft-tissue injury
and/or loss; previous implants and/or surgical procedures;
periosteal stripping; bone vascularity and/or loss; and blood
supply. Systemic host factors consist of age, nutrition, hypo-
thermia, immune function, smoking history, diabetes, co-
morbid chronic conditions, hypoxia, and endothelial
dysfunction57.
Acute and/or surgically modiﬁable factors for open
fractures can also inﬂuence outcomes and can include the type
of surgical procedure58, the stability of the fracture, the timing
of the surgical procedure59-61, the duration of antibiotics62, the
timing of systemic antibiotics62,63, local antibiotic delivery64,65,
the type of irrigant66-68, the length of hypotension, anemia, the
quality of debridement (reduction of local bioburden), the type
of wound closure69,70, the timing of wound closure71, and
avoidance of the second-hit phenomenon72. Recent literature
has suggested that these modiﬁable factors may directly or
indirectly affect bioﬁlm formation and thus represent
immunomodulation factors that can optimize healing of
the injury by the host’s immune system even in the presence
of presumed bioﬁlm.
Preoperative intravenous prophylactic antibiotic admin-
istration is effective, and recent literature pertaining to open
fractures has shown that administration of therapeutic intrave-
nous antibiotics within 1 hour of injury leads to improved
outcomes. Some delay in formal surgical debridement can be
accepted for low-grade open fractures, as the risk for presumed
bioﬁlm-related infection is decreased61. Reduction of the local
bioburden in open fractures involves irrigation and debridement
of the bone and soft tissues. Research has also demonstrated that
high-pressure irrigation does not lead to less reoperation com-
pared with low-pressure irrigation and may lead to additional
soft-tissue injury and delayed bone-healing66-68,73.
Assuming that the bioburden has been sufﬁciently
minimized after an open fracture, wound closure can be con-
sidered. Lower-grade open fractures can be considered for
wound closure at the initial surgical procedure58, but for high-
grade open fractures, delayed wound closure, including use
of adjuncts such as local antibiotics64,65 and negative-pressure
wound therapy devices, may lead to optimal limb salvage
rates69. Fracture stability and sufﬁcient fracture reduction
minimize soft-tissue shear and tension and can be achieved by
a variety of modalities. Intramedullary nailing of select open
fractures has been shown to have superior results compared
with external ﬁxation or plating74.
Because both osseous and soft-tissue injuries contribute
to the systemic inﬂammatory response, it is fair to assume that
appropriate surgical techniques can decrease bioburden and
can provide fracture stability, resulting in lower local inﬂam-
matory response (surgical immunomodulation)75,76. The above
comments assume that bioﬁlm can develop following an open
fracture, and currently we do not have the technology to
noninvasively quantify bioﬁlm activity and presence in a stable
open fracture following wound closure. Surgical judgment
and experience will be important in selecting the appropriate
tools and techniques to optimally treat open fractures.
Bioﬁlm in Total Joint Arthroplasty
Periprosthetic joint infections after total joint arthroplasty are
similar to infections in orthopaedic trauma in the sense that an
implant is normally present, and there can be a similar race to
the surface of implants, in which bone ingrowth competes with
bacterial growth. Even in the presence of preoperative antibi-
otics, staphylococcal and P. acnes bioﬁlms can form on implant
surfaces77. There are 3 main areas of recent investigation in this
ﬁeld: the diagnosis and imaging of bioﬁlms, bioﬁlm prevention,
and the treatment of bioﬁlms in periprosthetic joint infection.
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Diagnosis and Imaging
Molecular methods such as PCR have been used to aid in the
diagnosis of periprosthetic joint infection. However, recent
studies have indicated low sensitivity of detection using soft-
tissue and bone samples and have indicated that culture may
still be more effective, especially for detecting common organ-
isms (S. aureus, S. epidermidis, and P. aeruginosa)78,79. Imaging
may provide improved means for diagnosing bioﬁlm infec-
tions, although this requires direct visualization of implants or
direct access to implants to obtain samples. Molecular ﬂuo-
rescent staining with 16S rRNA FISH and use of confocal laser
scanning microscopy enables scientists to image bioﬁlms80.
Future methods of diagnosing bioﬁlm infection, including the
means to image bioﬁlmwithout the need for an incision, would
substantially improve the ability to detect, identify, and treat
these infections.
Prevention
The prevention of bioﬁlm formation in total joint arthroplasty
requires impregnating implants with antimicrobials, such as
antioxidants, antibiotics, and silver. The antioxidant vitamin
E was initially introduced into polyethylene to reduce free
radicals and to reduce oxidative wear in total joint arthroplasty.
Recent studies were contradictory with regard to bioﬁlm
prevention; one study demonstrated that vitamin E-blended
ultra-high molecular weight polyethylene was unable to
prevent bioﬁlm formation81, but another study demonstrated
that it decreased the adhesiveness of S. aureus and Escherichia
coli to this polyethylene in comparison with standard or
oxidized ultra-high molecular weight polyethylene82. However,
by adding a hydrophilic and antibioﬁlm layer of poly(2-
methacryloyloxyethyl phosphorylcholine) (PMPC)-graft to a
vitamin E-blended polyethylene, there was a hundredfold re-
duction in adherence of bioﬁlm83. Thus, antioxidants and other
coatings may hold promise for preventing future implant-
associated infections.
Previous studies have demonstrated that covalently
bonding antibiotics to titanium implants can inhibit bioﬁlm
formation84-86. More recent studies have shown that bioﬁlm
growth can be partially inhibited when PMMA cement is
combined with vancomycin and can be fully inhibited when
PMMA is mixed with both daptomycin and gentamicin87.
Antibiotics such as gentamicin can also be loaded in Fe3O4/
carbonated hydroxyapatite coatings to prevent bioﬁlm forma-
tion and to decrease bacterial adhesion, while still allowing the
implantation of devices in cementless total joint arthroplasty88.
Although antibiotics are useful agents for ﬁghting bac-
terial infections, there has been increased antibiotic resistance
and there are potentially harmful side effects from using these
drugs. Novel antimicrobial methods, such as the photosensi-
tizer RLP068/Cl, have been developed to disrupt bioﬁlms
without leading to antibiotic resistance89. Silver is a known
antimicrobial, and recent studies have evaluated the use of
silver in preventing bioﬁlm infections against Acinetobacter
baumannii, S. epidermidis, S. aureus, and P. aeruginosa when
coated on the surfaces of titanium alloys90,91. Finally, silver
nanoparticles have also been shown to be effective against
bioﬁlm formation when incorporated within acrylic bone
cement but not effective against planktonic bacteria92.
Treatment
Traditionally, bioﬁlm infections have been treated by 2-stage
exchange arthroplasty in the United States and 1-stage ex-
change arthroplasty in certain parts of Europe. Although bio-
ﬁlm from the implant is physically removed by extracting the
existing components, the potential exists for persistence of
bioﬁlm in the surrounding soft tissue. Most patients under-
going treatment for periprosthetic joint infection also receive
concomitant intravenous antibiotics, but a recent in vitro study
demonstrated that administering cefazolin even at increased
concentrations still resulted in persistent Staphylococcus bio-
ﬁlm on cobalt-chromium PMMA and polyethylene93. Addi-
tionally, pulse lavage was also demonstrated to be ineffective in
fully eradicating bioﬁlm and only provided a less-than-tenfold
reduction in bioﬁlm as measured with laser scanning confocal
microscopy imaging73. Similarly, low-frequency sonicationmay
not be able to treat bioﬁlm infections as fully as pulse lavage
can, and it may actually damage implants by increasing surface
roughness and may potentially reduce remaining articular
cartilage thickness94.
However, utilizing other chemical methods of eradicat-
ing bioﬁlm such as 2% to 4% chlorhexidine gluconate with
pulse irrigation for methicillin-resistant S. aureus bioﬁlm was
effective at reducing the colony-forming units of bacteria95. In
addition, the use of calcium sulfate loaded with vancomycin,
tobramycin, or a combination of vancomycin and tobramycin
reduced bioﬁlm formation and prevented bacterial coloniza-
tion but did not eradicate established bioﬁlm96.
Bioﬁlms are involved in all orthopaedic infections, es-
pecially cases where implants are present. To our knowledge,
there are no current guidelines in the United States for
treating these infections, and such guidelines will need to be
developed as we gain more understanding regarding bioﬁlm
development. Novel mechanical methods for disrupting
bioﬁlm will need to be developed so that bioﬁlms can be
detached from adherent surfaces, such as stainless steel,
cobalt-chromium, and titanium. Future developments in
pharmaceuticals, including the prevention of quorum sens-
ing, quorum quenching, and use of anti-cancer drugs may
provide us with new drugs for our armamentarium against
bioﬁlms. The opportunity is ripe to develop novel chemical
and mechanical means for treating bioﬁlm infections, and this
will be important to aid in the future eradication of ortho-
paedic infections.
Evidence-Based Orthopaedics
The editorial staff of The Journal reviewed a large number
of recently published research studies related to the
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musculoskeletal system that received a higher Level of Evidence
grade. In addition to articles cited already in the Update, 4
other articles with a higher Level of Evidence grade were
identiﬁed that were relevant to musculoskeletal infection. A list
of those titles is appended to this review after the standard
bibliography. We have provided a brief commentary about
each of the articles to help guide your further reading, in an
evidence-based fashion, in this subspecialty area.
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Evidence-Based Articles Related to Musculoskeletal
Infection
Chiang HY, Herwaldt LA, Blevins AE, Cho E, Schweizer ML. Effectiveness of
local vancomycin powder to decrease surgical site infections: a meta-analysis.
Spine J. 2014 Mar 1;14(3):397-407. Epub 2013 Oct 30.
Pooling the risk estimates from the 8 studies that assessed patients
undergoing spinal operations, local administration of vancomycin powder
appears to protect against surgical site infections, deep incisional surgical site
infections, and S. aureus surgical site infections.
Dumville JC, McFarlane E, Edwards P, Lipp A, Holmes A, Liu Z. Preoperative
skin antiseptics for preventing surgical wound infections after clean surgery.
Cochrane Database Syst Rev. 2015 Apr 21;4:CD003949.
A review of 13 studies found some evidence that preoperative skin
preparation for clean surgical cases with 0.5% chlorhexidine in methylated
spirits was associated with lower rates of surgical site infections than alcohol-
based povidone-iodine paint.
Sikorska H, Smoragiewicz W. Role of probiotics in the prevention and
treatment of meticillin-resistant Staphylococcus aureus infections. Int J Anti-
microb Agents. 2013 Dec;42(6):475-81. Epub 2013 Sep 7.
The evidence from a few small clinical studies indicates that administration
of speciﬁc probiotics may minimize methicillin-resistant S. aureus carriage.
Vuotto C, Longo F, Donelli G. Probiotics to counteract bioﬁlm-associated
infections: promising and conﬂicting data. Int J Oral Sci. 2014 Dec;6(4):189-94.
Epub 2014 Sep 26.
Accumulating evidence suggests that probiotics, especially lactobacilli,
positively affect oral, wound, and vaginal infections through a competition and
counteraction of pathogens.
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